(Q51540087)

6 April 2018

editorial

0 references

title

Bladder cancer pharmacogenomics: recent insights and future perspectives. (English)

1 reference

6 April 2018

1 reference

Peter H O'Donnell

1

1 reference

6 April 2018

publication date

1 November 2012

1 reference

6 April 2018

published in

Pharmacogenomics

1 reference

6 April 2018

volume

13

1 reference

6 April 2018

issue

14

1 reference

6 April 2018

page(s)

1553-1556

1 reference

6 April 2018

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

Current status of excision repair cross complementing-group 1 (ERCC1) in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

Study of the prediction system for clinical response to M-VAC neoadjuvant chemotherapy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

Prediction of drug combination chemosensitivity in human bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

Germline pharmacogenomics in oncology: decoding the patient for targeting therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.145

21 January 2018

Identifiers

DOI

10.2217/PGS.12.145

1 reference

6 April 2018

1 reference

6 April 2018